Zivo Bioscience Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Zivo Bioscience Inc (ZIVO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Zivo Bioscience Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 329,028M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+314.2% annualized vs trailing 12 months), vs holding steady (+1.7%) for its tracked peer group.
- Growth: Zivo Bioscience Inc generated 108.3% revenue growth year over year in Q3 2025, vs 0.8% for its tracked competitors combined.
- Profitability: Its -1,574.2% net margin compares with 14.9% for the peer group.
- Scale: Zivo Bioscience Inc ranks #137 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer revenue share: Zivo Bioscience Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.03M compares with $0.68M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ZIVO Sales vs. its Competitors, Q3 2025
Zivo Bioscience Inc reported revenue growth of 108.33 % year on year in Q3 2025, above its competitors' combined revenue growth of 0.83 %.
With a net margin of -1,574.18 %, Zivo Bioscience Inc reported lower profitability than its competitors (14.92 %).
Zivo Bioscience Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Zivo Bioscience Inc vs. its Competitors, Q3 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Zivo Bioscience Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Zivo Bioscience Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Zivo Bioscience Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs 108.3% for Zivo Bioscience Inc. Zivo Bioscience Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Zivo Bioscience Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Zivo Bioscience Inc | - | - | - | No |
| Competitors combined (19) | ||||
| High-Confidence Competitors (5) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ZIVO Stock Performance relative to its Competitors
ZIVO Stock Performance relative to High-Confidence Competitors
ZIVO Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Dupont De Nemours Inc | 282.9% | Outperformed |
| 2 | Darling Ingredients Inc | 282.9% | Outperformed |
| 3 | Johnson and Johnson | 282.9% | Outperformed |
| 4 | Bristol myers Squibb Company | 282.9% | Outperformed |
| 5 | Mama s Creations Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Zivo Bioscience Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Zivo Bioscience Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Zivo Bioscience Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Zivo Bioscience Inc | 12.60 | 0.06 |
| Johnson and Johnson | 652,897.56 | 97,929.00 |
| Abbott Laboratories | 176,384.49 | 45,134.00 |
| Pfizer Inc | 163,675.28 | 63,696.00 |
| Bristol myers Squibb Company | 128,737.28 | 49,186.00 |
| Dupont De Nemours Inc | 17,800.42 | 4,701.00 |
| SUBTOTAL | 1,217,273.52 | 329,027.90 |
Sign in to see all competitors of Zivo Bioscience Inc .
Sources: Zivo Bioscience Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Zivo Bioscience Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Zivo Bioscience Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| AG1 | Named by the company | 85% |
| Cyanotech | Named by the company | 85% |
| HuvePharma | Named by the company | 85% |
| ToDay | Named by the company | 85% |
| ConAgra | Named by the company | 85% |
| Elanco | Named by the company | 85% |
| Phibro | Named by the company | 85% |
| Well Roots Biotin Rich Plus Collagen | Named by the company | 85% |
| Cargill | Named by the company | 85% |
| DSM | Named by the company | 85% |
| Nestle | Named by the company | 85% |
| Verisol® | Named by the company | 85% |
| CoQ10 Supplement | Named by the company | 85% |
| Heliocare Skin Care Dietary Supplement | Named by the company | 85% |
| Pure Gold Collagen® | Named by the company | 85% |
| Zoetis | Named by the company | 85% |
| Cognis | Named by the company | 85% |
| Earthrise | Named by the company | 85% |
| Peptan® | Named by the company | 85% |
| Vitamin C | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Zivo Bioscience Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Zivo Bioscience Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Zivo Bioscience Inc | Microalgae Technology 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Dupont De Nemours Inc | Diversified Industrials 52.94 % |
| Mccormick and Company Incorporated | Consumer 59.01 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Zivo Bioscience Inc .
Zivo Bioscience Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Zivo Bioscience Inc | 13 | 31,685 | -4,242,888 |
| Johnson and Johnson | 652,898 | 695,518 | 149,411 |
| Abbott Laboratories | 176,384 | 392,470 | 54,574 |
| Pfizer Inc | 163,675 | 849,280 | 58,267 |
| Bristol myers Squibb Company | 128,737 | 1,513,415 | 285,354 |
| Dupont De Nemours Inc | 17,800 | 313,400 | 5,600 |
| PEERS TOTAL | 1,217,261 | 676,098 | 83,151 |
Sign in to see all peers for Zivo Bioscience Inc .
Zivo Bioscience Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 57.42 % |
| Abbott Laboratories | Non-US 61.62 % |
| Pfizer Inc | United States 58.91 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Dupont De Nemours Inc | United States 44.47 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Zivo Bioscience Inc .
Zivo Bioscience Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Zivo Bioscience Inc's industry classification, broader than the peer set above. Market cap in millions of $.Zivo Bioscience Inc ranks #137 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,320, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 227,218 | 25.72 % |
| 2 | Gilead Sciences Inc | 188,277 | 21.31 % |
| 3 | Moderna Inc | 81,799 | 9.26 % |
| 4 | Argenx Se | 63,476 | 7.19 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 137 | Zivo Bioscience Inc | 13 | 0.00 % |
Market cap and industry share for the rest of Zivo Bioscience Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Zivo Bioscience Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 132 | Tradeup Acquisition Corp | 20 | -60.17 % |
| 133 | Jasper Therapeutics Inc | 19 | -73.77 % |
| 134 | Dyadic International Inc | 16 | -56.31 % |
| 135 | Passage Bio Inc | 16 | -39.00 % |
| 136 | Genenta Science S p a | 1,234 | 12.3% |
| 137 | Zivo Bioscience Inc | 13 | - |
| 138 | Biocardia Inc | 1,234 | 12.3% |
| 139 | Brainstorm Cell Therapeutics inc | 1,234 | 12.3% |
| 140 | Intensity Therapeutics Inc | 1,234 | 12.3% |
| 141 | Pluri Inc | 1,234 | 12.3% |
| 142 | Senti Biosciences Holdings Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Zivo Bioscience Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-29. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Zivo Bioscience Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | -28.1x | 5.1x | -33.2x |
| Return on Equity | 426.45 % | industry aggregate | 414.24 % |
| Return on Invested Capital | 226.37 % | -6.17 % (avg) | 232.54 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Zivo Bioscience Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2016 | 2017 | 2018 | 2019 | 2021 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Return on Invested Capital | 18.49 % | 29.38 % | 20.74 % | 22.01 % | -179.46 % | 229.97 % | 423.30 % |
| P/E | - | - | - | - | 1,000,000,000,000.0x | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Zivo Bioscience Inc's BCG Growth-Share Matrix
Relative market share (vs Zivo Bioscience Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Zivo Bioscience Inc falls in the Question Mark quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Zivo Bioscience Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,320 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Zivo Bioscience Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Zivo Bioscience Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Zivo Bioscience Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Zivo Bioscience Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Zivo Bioscience Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 414.2 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+314.2% annualized vs trailing 12 months).
Weaknesses
- Low relative market share vs the industry leader (0.00x).
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Zivo Bioscience Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Zivo Bioscience Inc | 0.00 | 0.30 | - |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Abbott Laboratories | 0.47 | 1.60 | 0.35 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Dupont De Nemours Inc | 0.62 | 2.29 | 0.28 |
Sign in to see all peers for Zivo Bioscience Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Zivo Bioscience Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Zivo Bioscience Inc | Q3 2025 | +108.3 % | - |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Abbott Laboratories | Q1 2026 | +7.8 % | -18.7 % |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Dupont De Nemours Inc | Q2 2026 | -44.2 % | +110.0 % |
| PEERS TOTAL | +3.1 % | -26.1 % |
Sign in to see all peers for Zivo Bioscience Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Zivo Bioscience Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Zivo Bioscience Inc | Q3 2025 | +101.1 % | - |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Abbott Laboratories | Q1 2026 | +9.4 % | -17.6 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Dupont De Nemours Inc | Q2 2026 | +3.2 % | +52.0 % |
Sign in to see all peers for Zivo Bioscience Inc .
Zivo Bioscience Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Zivo Bioscience Inc | - | - | - |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Abbott Laboratories | 6.87% | 8.15% | 12.09% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Dupont De Nemours Inc | 0.33% | 0.36% | 0.51% |
Sign in to see all peers for Zivo Bioscience Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Zivo Bioscience Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Zivo Bioscience Inc | - | 198.78 |
| Johnson and Johnson | 30.97 | 6.67 |
| Abbott Laboratories | 28.12 | 3.91 |
| Pfizer Inc | 37.66 | 2.57 |
| Bristol myers Squibb Company | 13.84 | 2.62 |
| Dupont De Nemours Inc | 289.16 | 3.79 |
| PEERS AVERAGE | 30.09 | 3.70 |
Sign in to see all peers for Zivo Bioscience Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.